CEO Clifford on how Moximed has kept singularly focused on developing a shock absorber for the knee
Osteoarthritis isn’t a typical target for startups, but Moximed isn’t developing a typical device. In this episode, CEO Anton Clifford will walk us through the biomedical process that led to the decision to build a shock absorber that can stabilize an injured knee. The route has been long winding and has led the team over some bumpy roads, but Moximed is poised to deliver on its long-time promise.
At the start, co-hosts Tom Salemi and Chris Newmarker chat with Associate Editor Sean Whooley about Boston Scientific’s recent analyst day, with a tight focus on why Boston Scientific sees opportunity in China when other medical devices are withdrawing.
Notes for this episode:
Thanks for listening to the DeviceTalks Weekly Podcast
Subscribe to the DeviceTalks Podcast Network on any major podcast player.